Clayton Duncan
Vorstandsvorsitzender bei Pamlico BioPharma, Inc.
Profil
Clayton I.
Duncan was the founder of Synereca Pharmaceuticals, Inc. founded in 2009, where he held the title of Chairman & Chief Executive Officer.
Currently, he is the Chairman & Chief Executive Officer at Otologic Pharmaceutics, Inc. and Pamlico BioPharma, Inc. Mr. Duncan's former positions include Chairman, President & Chief Executive Officer at Incara Pharmaceuticals Corp., Chief Executive Officer at Entegrion, Inc., Chief Executive Officer at Sphinx Pharmaceuticals Corp, Chief Executive Officer at Ercole Biotech, Inc., Chief Executive Officer at Research Triangle Park, and Principal at Accele Venture Management LLC.
Mr. Duncan's education history includes an undergraduate degree from the University of California, Santa Barbara and an MBA from The University of North Carolina at Charlotte.
Aktive Positionen von Clayton Duncan
| Unternehmen | Position | Beginn |
|---|---|---|
Pamlico BioPharma, Inc.
 Pamlico BioPharma, Inc. BiotechnologyHealth Technology Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK. | Vorstandsvorsitzender | - |
Otologic Pharmaceutics, Inc.
 Otologic Pharmaceutics, Inc. Pharmaceuticals: MajorHealth Technology Otologic Pharmaceutics, Inc. develops treatment for acute hearing loss. Its product HPN1010 is an oral medication to treat acute hearing loss to reduce the development of permanent hearing disorders. The company was founded by Richard Kopke, Robert A. Floyd and Dave karlman and is headquartered in Oklahoma City, OK. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Clayton Duncan
| Unternehmen | Position | Ende |
|---|---|---|
Accele Biopharma, Inc.
 Accele Biopharma, Inc. Investment ManagersFinance Accele Biopharma, Inc. (Accele Biopharma) is a venture capital firm founded in 2011. The firm is headquartered in Oklahoma City, Oklahoma. | Vorstandsvorsitzender | 01.09.2017 |
| Incara Pharmaceuticals Corp. | Direktor/Vorstandsmitglied | 09.08.2004 |
| Sphinx Pharmaceuticals Corp | Corporate Officer/Principal | - |
Entegrion, Inc.
 Entegrion, Inc. Pharmaceuticals: MajorHealth Technology Entegrion, Inc. develops biological technologies, drugs, and pharmaceuticals. It applies public and private funds to design, develop, and deliver products that address unmet needs in military healthcare and have commercial applications. The company was founded by Arthur P. Bode in 2002 and is headquartered in Durham, NC. | Corporate Officer/Principal | - |
Ercole Biotech, Inc.
 Ercole Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sarepta Therapeutics, Inc., Ercole Biotech, Inc. develops splice switching drugs for the treatment of major human diseases. The company is based in Research Triangle Park, NC. The company was founded by Jorn Gorlach. Ercole Biotech was acquired by Sarepta Therapeutics, Inc. on March 20, 2008 for $8.25 million. | Corporate Officer/Principal | - |
Ausbildung von Clayton Duncan
| The University of North Carolina at Charlotte | Masters Business Admin |
| University of California, Santa Barbara | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
| Incara Pharmaceuticals Corp. | Health Technology |
Accele Venture Management LLC
 Accele Venture Management LLC Investment ManagersFinance Accele Venture Management LLC is a Venture Capital firm, a subsidiary of Accele Biopharma, Inc. founded in 2011. Accele Venture Management LLC is headquartered in Oklahoma City. | Finance |
Accele Biopharma, Inc.
Accele Biopharma, Inc. Investment ManagersFinance Accele Biopharma, Inc. (Accele Biopharma) is a venture capital firm founded in 2011. The firm is headquartered in Oklahoma City, Oklahoma. | Finance |
| Research Triangle Park | |
Synereca Pharmaceuticals, Inc.
 Synereca Pharmaceuticals, Inc. Medical DistributorsDistribution Services Synereca Pharmaceuticals, Inc. develops orally active drugs that restore the effectiveness of existing antibiotics. It focuses on compounds that enhance the activity of Colistin against gram-negative bacteria without enhancing its toxicity. The company was founded in 2009 by Clayton I. Duncan, Stephen B. Bocckino and Bennett W. Love and is headquartered in Oklahoma City, OK. | Distribution Services |
Ercole Biotech, Inc.
Ercole Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sarepta Therapeutics, Inc., Ercole Biotech, Inc. develops splice switching drugs for the treatment of major human diseases. The company is based in Research Triangle Park, NC. The company was founded by Jorn Gorlach. Ercole Biotech was acquired by Sarepta Therapeutics, Inc. on March 20, 2008 for $8.25 million. | Commercial Services |
Entegrion, Inc.
Entegrion, Inc. Pharmaceuticals: MajorHealth Technology Entegrion, Inc. develops biological technologies, drugs, and pharmaceuticals. It applies public and private funds to design, develop, and deliver products that address unmet needs in military healthcare and have commercial applications. The company was founded by Arthur P. Bode in 2002 and is headquartered in Durham, NC. | Health Technology |
| Sphinx Pharmaceuticals Corp | Health Technology |
Pamlico BioPharma, Inc.
Pamlico BioPharma, Inc. BiotechnologyHealth Technology Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK. | Health Technology |
Otologic Pharmaceutics, Inc.
Otologic Pharmaceutics, Inc. Pharmaceuticals: MajorHealth Technology Otologic Pharmaceutics, Inc. develops treatment for acute hearing loss. Its product HPN1010 is an oral medication to treat acute hearing loss to reduce the development of permanent hearing disorders. The company was founded by Richard Kopke, Robert A. Floyd and Dave karlman and is headquartered in Oklahoma City, OK. | Health Technology |
